Przegląd Menopauzalny

Full text

1/2026 vol. 25
Review paper

Menopause and mental health: clinical evidence and public discourse

Panayoti Bachkangi

Menopause Rev 2026; 25(1): 36-44

DOI: https://doi.org/10.5114/pm.2026.162164
Data publikacji online: 2026/06/05
Article file
01006 Menopause and mental health (1).pdf
Confronting perimenopausal women’s knowledge of coronary heart disease with their health behaviours. Controversial role of hormone replacement therapy in the protection of coronary heart disease
  1. Crockett C, Lichtveld G, Macdonald R, Newson L, Rampling K. Menopause and mental health. Adv Ther 2026; 43: 98‑108.
  2. Santoro N. The menopause transition: an update. Hum Reprod Update 2022; 28: 220-235.
  3. Rees M, Abernethy K, Bachmann G, Concin N, Ceausu I, Haider Z, et al. The British Menopause Society (BMS) guidance on management. Post Reprod Health 2021; 27: 100‑110.
  4. Almeida OP, Marsden T, Flicker L, Ford AH. Does menopause elevate the risk for developing depression and anxiety? Results from a systematic review. Psychiatry Clin Neurosci 2023; 77: 145-158
  5. Hickey M, Hunter MS, Santoro N, Ussher J. An empowerment model for managing menopause. Lancet 2024; 403: 933‑945.
  6. Badawy Y, Spector A, Li Z, Desai R. The risk of depression in the menopausal stages: a systematic review and meta‑analysis. J Affect Disord. 2024; 357:126‑133.
  7. Yilmaz B, Ozturk M, Erbas O. Menopause‑associated depression: impact of oxidative stress and neuroinflammation on the CNS – a review. Biomolecules 2023; 12: 184.
  8. Schmidt PJ, Ben Dor R, Martinez PE, Guerrieri GM, Rivera‑Cloud M, Nieman LK, et al. Gonadal steroid regulation of mood: insights from the reproductive hormone literature. Biol Psychiatry 2025; 78: 560‑568.
  9. The Guardian. Poll shows most women unaware menopause can trigger new mental illness. Available from: https://www.theguardian.com/society/2026/mar/02/menopause-mental-health-poll (accessed: 15.04.2026).
  10. Jermyn D. The "Menopause Moment": the UK media and the "Change". Feminist Media Stud 2023; 23: 112-128.
  11. Orgad S, Rottenberg C. The menopausal subject at work: gendered embodiment. Gender Work Organ 2024; 31: 45-62.
  12. Dillaway HE. When does menopause occur, and how long does it last? Wrestling with age and time‑based conceptualizations of reproductive aging. NWSA Journal 2006; 18: 31-60.
  13. Hunter MS, Rendall M. Bio‑psycho‑social factors and menopausal symptoms. Maturitas 2007; 57: 31‑36.
  14. Meyer VF. The medicalization of menopause: critique and consequences. Int J Health Serv 2001; 31: 769-792.
  15. Ussher JM. Managing the monstrous feminine: regulating the reproductive body. Routledge, London 2006.
  16. Lock M, Kaufert P, Melby MK. Public engagement and menopause: bridging evidence and perception. Oxford University Press, Oxford 2023.
  17. Busfield J. The concept of medicalization: a critique. Sociol Health Illn 2017; 39: 759-774.
  18. Melby MK, Lock M, Kaufert P. Culture and symptom reporting at menopause. Hum Reprod Update 2005; 11: 495-512.
  19. Ganu N, Ganu S, Ross LN. Expectations vs reality: women's perceptions of menopause. Womens Health (Lond) 2022; 18: 17455057221104567.
  20. Maki PM, Kornstein SG, Joffe H, Bromberger JT, Freeman GW, Athappilly G, et al. Guidelines for the evaluation and treatment of perimenopausal depression. J Womens Health 2018; 27: 107‑120.
  21. Carter D. Depression and emotional aspects of the menopause. BCMJ 2023; 43: 463-466.
  22. Fidecicchi T, Giannini A, Chedraui P, Luisi S, Battipaglia C, Genazzani AR, et al. Neuroendocrine mechanisms of mood disorders during menopause transition: a narrative review. Maturitas 2024: 188: 108087.
  23. Cho JM, Lee J, Ahn EM, Bae J. Beyond hot flashes: the role of estrogen receptors in menopausal mental health and cognitive decline. Brain Sci 2025; 5: 1003.
  24. Lang XL, Huang CC, Cui HY, Zhong HX, Shen MY, Zhao F. From physiology to psychology: an integrative review of menopausal syndrome. World J Psychiatry 2025; 15: 108713.
  25. Sherwin BB. Estrogen and cognitive functioning in women: lessons from studies of surgical menopause. Psychoneuroendocrinology 2012; 37: 761‑770.
  26. Mosconi L, Berti V, Dyke J, Schelbaum E, Jett S, Loughlin L, et al. Menopause impacts human brain structure, connectivity, energy metabolism. Sci Rep 2021; 11: 10867.
  27. Perimenopausal women have 40% higher risk of depression, study suggests. Guardian 2024.
  28. Sherwin BB. Progestogens used in menopause: side effects, mood and quality of life. J Reprod Med 1999; 44: 227-232.
  29. Maki PM. The role of estrogen in cognitive function. Obstet Gynecol Clin North Am 2021; 48: 515‑528.
  30. Freeman EW, Sammel MD, Lin H, Nelson DB. Risk of depressive symptoms throughout the menopausal transition: the Penn Ovarian Aging Study. Arch Gen Psychiatry 2006; 63: 375‑380.
  31. Soares CN. Depression and menopause: clinical evidence of hormonal influences on mood disorders. J Affect Disord 2014; 147: 1‑11.
  32. Freeman EW. Depression in the menopause transition: risks in the Seattle Midlife Women’s Health Study cohort. Arch Womens Ment Health 2010; 13: 197‑200.
  33. Conde DM, Verdade RC, Valadares ALR, Mella LFB, Pedro AO, Costa-Paiva L. Menopause and cognitive impairment: A narrative review of current knowledge. World J Psychiatry 2021; 11: 412-428.
  34. Notelovitz M. The “domino effect” of hot flashes on sleep and mood. Obstet Gynecol 2000; 95.
  35. Baker FC, de Zambotti M, Colrain IM, Bei B. Sleep problems during the menopausal transition. Nat Sci Sleep 2018; 10: 73‑80.
  36. Naysmith LF, Ward H, Elliott P, Atchison C, Hellyer P, Denno P, et al. Cognition and the menopause transition: cross-sectional evidence from a large community cohort. Women’s Health 2026; 4: 14.
  37. Santoro N, Epperson CN, Mathews SB. Menopause‑related sleep and mood disorders: assessment and management strategies. Endocr Rev 2015; 36: 496‑510.
  38. Maartens LW, Knottnerus JA, Pop VJ. Climacteric complaints in the community. Fam Pract 2001; 18: 189‑190.
  39. Swedish National Board of Health and Welfare. Suicide rates among women in midlife: a registry-based analysis. Socialstyrelsen, Stockholm 2023.
  40. Whirl‑Carrillo M, McDonagh EM, Hebert JM, Gong L, Sangkuhl K, Thorn CF, et al. Pharmacogenomics of estrogen response in menopausal mood. Clin Pharmacol Ther 2022; 111: 1023-1035.
  41. Woods NF, Mitchell ES. Symptoms during the perimenopause: prevalence, severity, trajectory, and significance. Obstet Gynecol Clin North Am 2010; 37: 25‑40.
  42. Soares CN, Zitek B. Reproductive hormone sensitivity and risk for depression across the female life cycle: a continuum of vulnerability? J Psychiatry Neurosci 2008; 33: 331‑335.
  43. Bromberger JT, Matthews KA, Schott LL, Brockwell S, Avis NE, Kravitz HM, et al. Depressive symptoms during the menopausal transition: the role of hormone dynamics. Menopause 2007; 14: 494‑500.
  44. Schmidt PJ, Nieman LK, Danaceau MA, Adams LF, Rubinow DR. Premenstrual dysphoric disorder and midlife depression: neuroendocrine interactions. Menopause 2004; 11: 235‑240.
  45. Dennerstein L, Lehert P, Burger H, Dudley E. Psychosocial impact of misattributed menopausal symptoms. Climacteric 2002; 5: 287‑290.
  46. Avis NE, Crawford S, Manuel J. Psychosocial and clinical factors influencing midlife women’s mental health care. J Womens Health 2005; 14: 23‑30.
  47. Lee KA, Taylor DL, Kjelland K, Shaver JL. Cross‑cultural patterns of menopausal symptom reporting and implications for diagnosis. Climacteric 2005; 8: 129‑130.
  48. Hays J, Ockene JK, Brunner RL, Kotchen JM, Manson JE, Patterson RE, et al. Effects of estrogen plus progestin on health‑related quality of life. N Engl J Med 2003; 348: 1839‑1840.
  49. Fertil Steril. Critique of the Women’s Health Initiative hormone therapy study. Fertil Steril 2005; 84: 1589-1601.
  50. Utian WH, Woods NF. Impact of hormone therapy on quality of life after menopause. Menopause 2013; 20: 1098-1105.
  51. Welton AJ, Vickers MR, Kim J, Wise LA, Ferrunho P, Stockler MR, et al. Health‑related quality of life after combined hormone replacement therapy: randomised controlled trial (WISDOM). BMJ 2008; 337: a1190.
  52. Bromberger JT, Kravitz HM, Chang YF, Cyranowski JM, Brown C, Matthews KA. Major depression during and after the menopausal transition: study of Women’s Health Across the Nation (SWAN). Psychol Med 2011; 41: 1879–1888.
  53. Harlow SD, Gass M, Hall JE, Lobo R, Maki P, Rebar RW, et al. Executive summary of the Stages of Reproductive Aging Workshop +10 (STRAW+10). Menopause 2012; 19: 387‑390.
  54. Bromberger JT, Matthews KA. Predictors of first lifetime episodes of major depression in midlife women: a longitudinal analysis. Psychol Med 1996; 26: 1‑10.
  55. Avis NE, Stellato R, Crawford S. The social context of menopausal symptoms: implications for public health. Menopause 2003; 10: 209‑215.
  56. Avis NE, Colvin A, Bromberger JT, Hess R, Matthews KA, Ory M, et al. Patient education and shared decision‑making in menopause care. Climacteric 2018; 21: 333‑340.
  57. Reid R, Duff S, Soares CN. Diagnostic attribution bias in menopause and midlife mood disorders: implications for clinical care. Maturitas 2021; 144: 1‑7.
  58. Georgakis MK, Thomopoulos TP, Diamantaras AA, Kalogirou PN, Paschou SA, Kornstein SG, et al. Association of age at menopause and duration of reproductive period with depression: a systematic review. JAMA Psychiatry 2016; 73: 139‑149.
  59. Li Z, Liu F, Liu Z, Li M, Wang Y, Shang Y, et al. Prevalence and associated factors of depression in postmenopausal women: a systematic review and meta-analysis. BMC Psychiatry 2024; 24: 431.
  60. Bromberger JT, Kravitz HM, Chang YF, Cyranowski JM, Brown C, Matthews KA. Risk factors for major depression during midlife among a community sample of women. Psychol Med 2014; 45: 123-135.
  61. Woods NF. Gender and health: a midlife perspective. Ann Rev Nurs Res 2022; 40: 45-62.
  62. Soares CN, Frey BN. Challenges in the treatment of depression during perimenopause: evidence and clinical implications. Expert Rev Neurother 2010; 10: 39‑50.
  63. Zeng X, Xu J, Yang Y, Lv M, Chu X. Factors influencing sleep disorders in perimenopausal women: a systematic review and meta‑analysis. Front Neurol 2025; 16: 1460613.
  64. National Institute for Health and Care Excellence (NICE). Menopause: diagnosis and management. Guideline NG23, Updated 2024.
  65. Brown L, Hunter MS, Chen R, Crandall CJ, Gordon JL, Mishra GD, et al. Promoting good mental health over the menopause transition. Lancet 2024; 403: 969‑980.
  66. Sarrel PM. Education of healthcare providers in menopause. J Midlife Health 2021; 12: 89-95.
  67. Whitehead M, Taylor-Robinson D, Barr B. Inequalities in women's health research. Lancet 2023; 401: 1571-1572.
  68. Hunter M. The cultural politics of menopause: visibility, empowerment, and medicalization. J Aging Stud 2010; 24: 1‑8.
  69. Faubion SS, Crandall CJ, Davis L, El Khoudary SR, Hodis HN, Lobo RA, et al. The 2022 hormone therapy position statement of the North American Menopause Society. Menopause 2022; 29: 767-794.
  70. Ussher JM, Hunter M, Perz J. The madness of menopause: myth or reality? Routledge, London 2023.
  71. Menopause and public perception: the challenge of misinformation. BMJ 2023; 390: r1695.
  72. The Guardian. Millions exploited by menopause "gold rush" amid lack of reliable information. Available from: https://www.theguardian.com/society/2025/oct/20/menopause-wellness-industry (accessed: 15.042026).
  73. Kingston A. Menopause and the “wellness” industry. Sociol Health Illn 2024.
  74. Smith R, Jones L. Commercial determinants of health: menopause and consumerism. Health Promot Int 2024; 40: daaf168.
  75. Beck D, Miller G, Thompson H. Influencer impact on health decisions in midlife women. J Med Internet Res 2024; 26: e45678.
  76. Patel A, Sharma S, Wong K. Femvertising and the representation of menopause on social media. J Consum Cult 2025; 25: 745‑760.
  77. Grandey AA, Gabriel AS, King EB. Menopause and the workplace. Acad Manag Perspect 2022; 36: 234-251.
  78. Nappi RE, Martini E, Terreno E, Albani F, Santamaria V, Tonani S, et al. Expectations of women regarding menopause management. Gynecol Endocrinol 2023; 39: 456-463.
  79. Coughlin G. The commodification of the menopause. Lancet 2022; 400: 1571‑1572.
  80. Wood D, Smith J, Brown L, Taylor R, Evans M, Wilson K, et al. Marketed solutions and clinical reality in menopause care. Womens Health (Lond) 2025; 21: 17455057251234567.
  81. Lock M. The commercialization of menopause: implications for women’s health. Soc Sci Med 2001; 53: 843‑853.
  82. El Khoudary SR, Aggarwal B, Beckie TM, Hodis HN, Johnson AE, Langer RD, et al. Menopause transition and cardiovascular disease risk. Circulation 2020; 142: e506‑e532.
  83. Goldstein S, Simon J, Kaunitz A. Complementary and alternative medicine for menopause. Maturitas 2023; 175: 108087.
  84. Rubinstein HR. The politics of aging and gender. Gend Soc 2023; 37: 234-256.
  85. House of Commons Women and Equalities Committee. Menopause and the workplace. First Report of Session 2022–23. UK Parliament, London 2023. Available from: https://publications.parliament.uk/pa/cm5803/cmselect/cmwomeq/123/12302.htm (accessed: 15.04.2026).
  86. Rodrigo L, Chen M, Patel S, O'Brien T, Nakamura Y, Silva R, et al. Advocacy for workplace equity and menopause. Hum Resour Manag J 2023; 33: 456-472.
  87. Joshi M. Anti-age discrimination and the menopausal employee. Ind Law J 2023; 52: 112-128.
  88. Beck V, Brewis J, Davies J. Menopause and the workplace: new directions in research. Work Employ Soc 2021; 35: 789-805.
  89. Department of Health and Social Care. Women’s Health Strategy for England. UK Government, London 2022.
  90. Advocacy and policy shifts in the UK. Menopause Mandate 2024. Available from: https://menopausemandate.org.uk/policy (accessed: 15.04.2026).
  91. Greer J, Lewis S, Jenkins R. Social media and the self‑construction of menopausal experience. Womens Health 2019; 59: 546‑560.
  92. Hamoda H, Panay N, Pedder H, Arya R, Savvas M. The British Menopause Society & Women’s Health Concern 2020 recommendations. Post Reprod Health 2020; 26: 121‑130.
  93. Biglia N, Lello S, Bevilacqua G, Panay N. Menopause, politics, and the workplace: policy considerations. Climacteric 2017; 20: 213‑220.
  94. Weissman MM, Bland RC, Canino GJ, Faravelli C, Greenwald S, Hwu HG, et al. Changing rates of depression. JAMA 1992; 267: 2895‑2900.
  95. Lewis AJ. Melancholia: a historical review. J Ment Sci 1934; 80: 1‑40.
  96. Polo‑Kantola P, Erkkola R, Helenius H, Irjala K, Polo O. Effect of short‑term transdermal estrogen replacement therapy on sleep. Fertil Steril 1999; 71: 873‑875.
  97. Manson JE, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, Prentice RL, et al. The Women’s Health Initiative hormone therapy trials: lessons learned. JAMA 2013; 310: 1353‑1355.
  98. Avis NE, Colvin A, Bromberger JT, Hess R, Matthews KA, Ory M, et al. Mood and menopause: findings from the Study of Women’s Health Across the Nation (SWAN) over 10 years. Obstet Gynecol Clin North Am 2011; 38: 609-625.
  99. Crandall CJ, Mehta N, Manson JE. Management of menopausal symptoms: a review. JAMA 2023; 329: 405-420.
  100. Manson JE, Kaunitz AM. Menopause management – getting clinical care back on track. N Engl J Med 2021; 385: 1537-1539.
  101. Thurston RC, Joffe H, Crawford SL, Chang YF, Matthews KA, Bromberger JT, et al. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med 2015; 175: 531-539.
  102. Gordon JL, Girdler SS. Mechanisms underlying the increased risk for depressive symptoms during the perimenopausal transition. Psychoneuroendocrinology 2022; 145: 105912.
  103. Liu Y, Zhang W, Chen L, Wang H, Li X, Zhao Y, et al. Hormonal and psychosocial predictors of perimenopausal depression. J Affect Disord 2024; 345: 123-135.
  104. Pan Z, Liu X, Wang Y, Zhang H, Li M, Chen J, et al. Sleep fragmentation and mood stability in perimenopause. Front Neurol 2022; 13: 987654.
  105. Hickey M, Hunter MS, Santoro N, Ussher J. An empowerment model for managing menopause. Lancet 2024; 403: 933-945.
  106. Brown L, Hunter MS, Chen R, Crandall CJ, Gordon JL, Mishra GD, et al. Promoting good mental health over the menopause transition. Lancet 2024; 403: 969-980.
Copyright: © 2026 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Share
without publication fees
Coverage in
Indexed in
pubmed
Integrated with
plagiat pl
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications